This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

开始日期2023-12-05

申办/合作机构

BriaCell Therapeutics Corp.

NCT03328026 / Enrolling by invitation临床1/2期

A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab

This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy.
Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3 weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients (dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an expansion cohort of up to 24 patients will be treated with that combination. These will be randomized to two regimens differing in the timing of checkpoint inhibitor administration.

开始日期2018-03-16

申办/合作机构

BriaCell Therapeutics Corp.

[+1]

NCT03066947 / Completed临床1/2期

A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose cyclophosphamide 2-3 days before the inoculation; inoculation in 4 sites on the thighs and upper back; and post-treatment inoculation of Interferon-alpha-2b into the sites of inoculation
2 and
4 days after the inoculation. These is repeated every 2 weeks for one month (3 treatments), then monthly for up to one year. Standard tumor assessments are performed at baseline and then every 2-3 months.

开始日期2017-05-05

申办/合作机构

BriaCell Therapeutics Corp.

[+1]

100 项与 SV BR 1 GM cancer vaccine ( BriaCell Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 SV BR 1 GM cancer vaccine ( BriaCell Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 SV BR 1 GM cancer vaccine ( BriaCell Therapeutics) 相关的专利（医药）

登录后查看更多信息

项与 SV BR 1 GM cancer vaccine ( BriaCell Therapeutics) 相关的文献（医药）

2023-05-01·Recent patents on anti-cancer drug discovery

Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response

作者: Sunkari, Vivekananda G. ; Williams, William V. ; Lacher, Markus D. ; Macúchová, Eva ; Hashwah, Hind ; Dozio, Vito ; Galeas, Jacqueline L. ; Kharazi, Alexander ; Wiseman, Charles L.

Background::

SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pending and granted patents.

Methods::

We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovarian cancer subjects. Inoculations were preceded by low-dose intravenous cyclophosphamide and followed by interferon-alpha2b injections into the SV-BR-1-GM inoculation sites. We assessed both cellular and humoral immune responses, and measured expression levels of SV-BR-1-GM HLA alleles.

Results::

Treatment was generally safe and well tolerated. Immune responses were elicited universally. Overall survival was more than 33 months for three of the four patients. As previously reported, one patient had prompt regression of metastases in lung, breast, and soft tissue. Following cessation of treatment, the patient relapsed widely, including in the brain. Upon retreatment, rapid tumor response was again seen, including complete regression of brain metastases. Consistent with a role of Class II HLA in contributing to SV-BR-1-GM’s mechanism of action, this patient allele-matched SV-BR-1-GM at the HLA-DRB1 and HLA-DRB3 loci. We are in the process of developing next-generation SV-BR-1-GM, expressing patient-specific HLAs. Patent applications were filed in various jurisdictions. Thus far, one is granted, in Japan.

Conclusion::

A whole-cell immunotherapy regimen with SV-BR-1-GM cells induced regression of met-astatic breast cancer. We develop intellectual property based on SV-BR-1-GM’s predicted mechanism of action to develop additional whole-cell immunotherapies for cancer patients.

Clinical Trail Registration::

This clinical trial was registered under ClinicalTrials.gov Identifier NCT00095862.

2015-07-01·Anesthesiology1区 · 医学

Effects of an Innovative Psychotherapy Program for Surgical Patients

1区 · 医学

Article

作者: Neuner, Bruno ; Balzer, Felix ; Brähler, Elmar ; Kerper, Léonie F. ; Krampe, Henning ; Salz, Anna-Lena ; Tafelski, Sascha ; Neumann, Tim ; Spies, Claudia D. ; Glaesmer, Heide ; Weiß-Gerlach, Edith ; Wernecke, Klaus-Dieter ; Romanczuk-Seiferth, Nina ; Lau, Alexandra

Abstract:

Background::

The stepped care program Bridging Intervention in Anesthesiology (BRIA) aims at motivating and supporting surgical patients with comorbid mental disorders to engage in psychosocial mental healthcare options. This study examined the efficacy of BRIA.

Methods::

This randomized, parallel-group, open-label, controlled trial was conducted in the preoperative anesthesiological assessment clinics and surgical wards of a large university hospital in Germany. A total of 220 surgical patients with comorbid mental disorders were randomized by using the computer-generated lists to one of two intervention groups: BRIA psychotherapy sessions up to 3 months postoperatively (BRIA) versus no psychotherapy/computerized brief written advice (BWA) only. Primary outcome was participation in psychosocial mental healthcare options at month 6. Secondary outcome was change of self-reported general psychological distress (Global Severity Index of the Brief Symptom Inventory) between baseline and month 6.

Results::

At 6-month follow-up, the rate of patients who engaged in psychosocial mental healthcare options was 30% (33 of 110) in BRIA compared with 11.8% (13 of 110) in BWA (P = 0.001). Number needed to treat and relative risk reduction were 6 (95% CI, 4 to 13) and 0.21 (0.09 to 0.31), respectively. In BRIA, Global Severity Index decreased between baseline and month 6 (P < 0.001), whereas it did not change significantly in BWA (P = 0.197).

Conclusions::

Among surgical patients with comorbid mental disorders, BRIA results in an increased engagement in subsequent therapy options and a decrease of general psychological distress. These data suggest that it is reasonable to integrate innovative psychotherapy programs into the context of interdisciplinary surgical care.

2004-09-01·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT.

Article

作者: Bröer, Stefan ; Langen, Karl-Josef

项与 SV BR 1 GM cancer vaccine ( BriaCell Therapeutics) 相关的新闻（医药）

2024-09-18

·GlobeNewswire-Health Care

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT™ to those cancer patients in need beyond the scope of BriaCell’s pivotal Phase 3 clinical trial. PHILADELPHIA and VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce U.S. FDA (FDA) authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) patients. FDA requires BriaCell to have an EAP policy, as a condition of granting BriaCell’s Fast Track designation, and to help MBC cancer patients in need of novel treatments. The EAP provides access to cancer patients beyond the scope of BriaCell’s pivotal Phase 3 trial (ClinicalTrials.gov as NCT06072612) to receive treatment with the Bria-IMT™ regimen. “FDA authorization for the EAP highlights its awareness of the safety and efficacy profile of Bria-IMT™ and patients’ need to access such a novel treatment. While we are conducting our pivotal Phase 3 trial of Bria-IMT™ regimen with an immune checkpoint inhibitor, Bria-IMT™ may provide a treatment option for cancer patients in need,” stated Dr. William V. Williams, BriaCell’s President and CEO. “Despite numerous approved drugs, breast cancer remains the second leading cause of cancer death in American women. With our novel immunotherapy, we expect to bring hope to patients and families suffering from this deadly disease.” “Given the recently reported impressive survival and clinical benefit of Bria-IMT™ regimen in metastatic breast cancer patients who failed multiple prior treatments, more patients would be able to benefit from the EAP with BriaCell’s novel immunotherapy approach,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “We hope that our novel immunotherapy will become a new standard of care for metastatic breast cancer patients.” For additional information on BriaCell’s EAP program, please visit: https://briacell.com/eap/. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Further, certain forward-looking statements, including statements about the Company's belief of the therapeutic potential of Bria-IMT™ for metastatic breast cancer patients, are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Media Relations:Jules AbrahamCORE IRjulesa@coreir.com Investor Relations Contact:CORE IRinvestors@briacell.com

免疫疗法临床3期快速通道

2024-09-12

·GlobeNewswire-Health Care

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering priced at-the-market under Nasdaq rules for 12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million, before deducting placement agent fees and other offering expenses. All the shares in the offering were offered by the Company. The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives. ThinkEquity acted as sole placement agent for the offering. The securities were offered and sold pursuant to the Company’s currently effective shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. The offering was made by means of a prospectus supplement and prospectus which have been filed with the SEC and available on the SEC’s website at www.sec.gov. You should read the applicable prospectus supplement and prospectus for more complete information about the Company and the offering. You may obtain these documents free of charge by visiting the SEC website at www.sec.gov. Alternatively, you may obtain copies by contacting ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About BriaCell Therapeutics Corp.BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Forward-Looking StatementsThis press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell replicating positive data in its ongoing Phase 3 study; BriaCell’s Bria-IMT™ regimen bringing relief to cancer patients whose medical needs remain unmet; and the Bria-IMT™ regimen becoming a therapeutic option for metastatic breast cancer patients, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Media Relations:Jules AbrahamCORE IRjulesa@coreir.com Investor Relations Contact:CORE IRinvestors@briacell.com

免疫疗法临床3期

2024-09-11

·GlobeNewswire-Health Care

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literatureOngoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer populationNo drug related discontinuations to date PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer. Median overall survival of 15.6 months is reported in BriaCell’s most recent patients (treated since 2022) vs. 6.7-9.3 months for similar patients reported in the literature (see table below). These patients are being treated with the same Bria-IMT™ formulation currently being used in BriaCell’s ongoing Phase 3 pivotal study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612) and represent patients enrolled post-COVID when full study activities resumed. This represents a substantial improvement over BriaCell’s 13.4 months median overall survival previously reported in December 2023. “Overall survival in patients with heavily pre-treated metastatic breast cancer is very poor,” stated Sara A. Hurvitz, MD, Professor of Medicine, Fred Hutch Cancer Center and University of Washington and BriaCell medical advisory board member. “The BriaCell early data is quite encouraging from both efficacy and tolerability standpoints.” “We wanted to look at the Phase 2 data of those patients who most closely resemble the patients being treated in our ongoing phase 3 study and compare them to similar patients in the literature,” stated Dr. William V. Williams, BriaCell’s President and CEO. “The nearly two-fold overall survival benefit we are seeing with the Bria-IMT™ regimen, together with the similar previously reported approximate doubling of progression free survival, compared with literature controls, strongly support our belief that Bria-IMT™ could have a meaningful impact in the lives of heavily pre-treated metastatic breast cancer patients. We look forward to further clinical development of Bria-IMT™ with the goal of establishing it as a new standard of care for patients with metastatic breast cancer.” “The Bria-IMT™ regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated metastatic breast cancer patients who have failed numerous prior treatments including immune check point inhibitors and antibody drug conjugates,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “These survival and clinical benefit data support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and drive the ongoing pivotal study of our combination regimen in the treatment of metastatic breast cancer.” The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (average number of prior treatments = 6) who were treated with the Bria-IMT™ regimen and an immune checkpoint inhibitor. Of these 54 patients, 37 were treated with the Phase 3 formulation and 25 of these were treated post-COVID when full study activities resumed. This data represents an additional six months of follow-up of the survival data presented at the San Antonio Breast Cancer Symposium in December 2023. Table 1. Comparative Median Overall Survival (OS) and Progression-Free Survival (PFS) in Similar Patients (Interim Analysis Using Kaplan-Meier Estimate) StudyPrior Lines of Therapy (median, range)Number of PatientsOS (months)PFS (months) BriaCell’s Phase 2 study patients who received pivotal Phase 3 study formulation (since 2022)5.5 (2-13)2515.64.1 BriaCell’s Phase 2 study patients who received pivotal Phase 3 study formulation (total)6 (2-13)3713.43.9 Bardia, A. et. al. 1 (TNBC)4 (2-14)2626.91.7 Tripathy D. et. al. 2 (Brain metastases)≥4 in 91%1787.5-7.81.9-2.8 O’Shaughnessy J. et. al. 3non-TNBC at initial diagnosis5 (2-14)766.72.3 O’Shaughnessy J. et. al. 3TNBC at initial diagnosis4 (2-10)1576.91.6 Cortes et. al. 44 (0-13)5949.1-9.31.9-2.5 References Bardia A, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. doi: 10.1200/JCO.23.01409. Epub 2024 Feb 29. PMID: 38422473.Tripathy D, et al. Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial. JAMA Oncol. 2022;8(7):1047-1052. doi:10.1001/jamaoncol.2022.0514.O’Shaughnessy J et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. PMID: 35545724; PMCID: PMC9374646.Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051. PMID: 29481630. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including statements about: the impact of Bria-IMT™ on patients with metastatic breast cancer; BriaCell’s further clinical development of Bria-IMT™; and the efficacy of immune check point inhibitors, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Media Relations:Jules AbrahamCORE IRjulesa@coreir.com Investor Relations Contact:CORE IRinvestors@briacell.com

临床3期免疫疗法临床2期临床结果

100 项与 SV BR 1 GM cancer vaccine ( BriaCell Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	美国	BriaCell Therapeutics Corp.	2023-12-05
转移性乳腺癌	临床2期	美国	LumaBridge LLC初创企业	2017-05-05
转移性乳腺癌	临床2期	美国	BriaCell Therapeutics Corp.	2017-05-05
卵巢上皮癌	临床1期	美国	BriaCell Therapeutics Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06072612 (GlobeNewswire) 人工标引	临床2期	转移性乳腺癌	54	Bria-IMT™ regimen + immune checkpoint inhibitor (since 2022)	夢觸範鏇衊遞網製觸壓(膚願衊夢願艱鬱壓簾鏇) = 鏇獵範積淵襯鏇願願壓糧鹹觸衊積蓋獵衊構願 (製網餘醖艱簾鑰積獵夢 ) 更多	积极	2024-09-11
NCT06072612 (GlobeNewswire) 人工标引	临床2期	转移性乳腺癌	54	Bria-IMT™ regimen + immune checkpoint inhibitor (total)	夢觸範鏇衊遞網製觸壓(膚願衊夢願艱鬱壓簾鏇) = 簾糧範衊廠繭壓蓋鹽蓋糧鹹觸衊積蓋獵衊構願 (製網餘醖艱簾鑰積獵夢 ) 更多	积极	2024-09-11
NCT03328026 (ASCO2024) 人工标引	临床1/2期	转移性乳腺癌 \| 晚期乳腺癌 CAMLs \| CTCs	54	SV-BR-1-GM±pembrolizumab±retifanlimab	憲鏇構範餘醖積顧簾繭(壓遞鬱齋觸遞壓繭襯構) = 壓餘範蓋構網鬱製遞範獵構憲製鑰鏇遞齋夢醖 (醖獵鹹艱糧醖蓋願襯繭 ) 更多	积极	2024-05-24
NCT03328026 (SV-BR-1-GM, ASCO2024)	临床2期	转移性乳腺癌	54	Bria-IMT + CPI	繭鹽遞觸積夢鹽窪鑰鏇(觸鹽齋膚簾夢範遞積襯) = 43% (10/23) reported grade 3 or 4 AEs, independent of study drug causality. AEs included injection site reaction (39%), fatigue (26%), and nausea/vomiting (43%), mostly mild to moderate. One case of elevated lipase was the most clinically significant grade 4 AE. No interstitial lung disease (ILD) was reported. 遞艱鏇蓋衊糧餘鹽顧築 (積糧築窪壓製獵襯獵艱 ) 更多	积极	2024-05-24
AACR2024	临床2期	转移性乳腺癌	23	Bria-IMT™ + CPI	築選憲蓋築壓艱廠鬱簾(築構選簾網製選獵廠願) = 43% (10/23) reported grade 3 or 4 AEs, independent of study drug causality. No interstitial lung disease (ILD) reported. AEs included injection site reaction (39%), fatigue (26%), and nausea/vomiting (43%), mostly mild to moderate. One case of elevated lipase was the most clinically significant grade 4 AE. 積艱淵淵蓋顧鑰簾醖鬱 (網餘衊廠顧鹽構選繭糧 ) 更多	-	2024-04-05
AACR2024	N/A	肿瘤转移 ER+/PR+ \| HER2- \| ER-/PR- ... 更多	-	Bria-IMT monotherapy	範鹹襯淵鏇簾艱鹹糧襯(淵選遞艱鬱窪淵積襯襯) = 餘壓鬱選淵獵蓋醖憲繭製窪顧糧簾鏇襯願範鹽 (積廠遞範餘網餘繭獵築 )	-	2024-04-05
AACR2024	N/A	肿瘤转移 ER+/PR+ \| HER2- \| ER-/PR- ... 更多	-	Bria-IMT + immune checkpoint inhibitor	範鹹襯淵鏇簾艱鹹糧襯(淵選遞艱鬱窪淵積襯襯) = 鬱獵夢願觸襯蓋構蓋繭製窪顧糧簾鏇襯願範鹽 (積廠遞範餘網餘繭獵築 )	-	2024-04-05
GlobeNewswire 人工标引	N/A	晚期乳腺癌	-	Bria-IMT±Checkpoint Inhibitor	壓構構繭繭夢鑰觸獵鬱(蓋鑰範鹽鹽繭醖糧鹹膚) = 衊鹹製簾廠鏇窪蓋襯蓋蓋獵艱製憲鏇積齋顧醖 (鏇構窪憲鹽蓋衊艱製願 )	积极	2023-12-28
NCT03328026 (Biospace) 人工标引	临床2期	转移性乳腺癌	54	Bria-IMT+CPI	網積簾觸繭齋鬱獵憲廠(網夢夢齋顧簾獵選襯鹽) = 網淵糧鹽獵鹽網鬱顧齋鹹餘餘窪製憲餘簾獵艱 (夢鹹鑰糧鑰襯窪鹹觸膚 ) 更多	积极	2023-12-06
NCT03328026 (Bria-IMT, SABCS2023)	临床2期	转移性乳腺癌 hormone receptor positive \| HER2 negative \| HER2 low ... 更多	25	Bria-IMT + PD-1 checkpoint inhibitor	淵觸鹹餘蓋壓鹽獵製糧(構鏇鑰獵獵鏇鑰醖範齋) = 繭構製壓鏇簾壓醖餘餘構齋簾廠齋構齋醖製餘 (艱簾醖願選鹽衊選衊廠 ) 更多	积极	2023-12-05
NCT03328026 (Bria-IMT, SABCS2023)	临床2期		25	Control arm (original sequence with simultaneous start of Bria-IMT and CPI in cycle 1)	遞襯壓鏇顧鹹憲糧餘積(網願鹹夢遞鏇糧網襯蓋) = 鏇鏇網襯鹽顧範築網膚艱蓋鹽觸齋憲淵獵憲窪 (衊壓膚廠顧鹹願構艱築 )	积极	2023-12-05
GlobeNewswire 人工标引	临床2期	HR阳性/HER2阳性乳腺癌 Hormone Receptor Positive \| Hormone Receptor/HER2 Positive	1	Bria IMT	觸顧餘鹽襯窪窪餘積齋(蓋顧築網齋蓋遞窪蓋簾) = After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. 鑰襯築遞齋簾鏇鬱鹹鬱 (憲顧糧範鬱範蓋繭醖願 ) 更多	积极	2023-11-30
NCT03066947 \| NCT03328026 (AACR2023) 人工标引	临床1/2期	转移性乳腺癌	51	SV-BR-1-GM	積鬱簾選憲鏇膚鑰艱襯(構構鏇餘觸鑰簾餘齋憲) = 淵壓蓋糧遞餘窪製簾襯衊膚觸餘鹹願餘築窪鏇 (廠獵網壓膚夢醖蓋鹹鏇 ) 更多	积极	2023-04-14
NCT03066947 \| NCT03328026 (AACR2023) 人工标引	临床1/2期	转移性乳腺癌	51	SV-BR-1-GM+Pembrolizumab or Retifanlimab	積鬱簾選憲鏇膚鑰艱襯(構構鏇餘觸鑰簾餘齋憲) = 壓壓糧鹽鹽獵衊窪窪窪衊膚觸餘鹹願餘築窪鏇 (廠獵網壓膚夢醖蓋鹹鏇 ) 更多	积极	2023-04-14